Intravenous ImmunoGlobulins
In Multiple Sclerosis

Lisak RP
Neurology 1998 Dec;51(6 Suppl 5):S25-9
Dept of Neurology,
Wayne State Univ, School of Medicine,
Detroit Medical Center, Michigan, USA
UI # 99067052

The spectrum of diseases being treated with IntraVenous ImmunoGlobulins (IVIg) appears to be ever broadening, including use in Neurologic diseases.

After a period of anectodal reports and smaller uncontrolled series, recently there have been several randomized, prospective, double-blind, placebo-controlled studies employing IVIg in patients with Relapsing/Remitting (RR) Multiple Sclerosis (MS).

Reduction in relapse rate and some evidence of decreased MRI activity has been reported, but to date no effect on disability or MRI lesion burden has been noted.

Because of differences in methodologic design and patient populations, as well as the relatively small number of patients in some of these studies, a rigorous direct comparison of efficacy with the type I Interferons and Glatiramer Acetate is not possible.

Given these data and the high cost of IVIg, routine use of this mode of therapy cannot be recommended, certainly not as a first-line treatment. Larger studies would clearly be helpful. At present there is no evidence to support the use of IVIg in Secondary Progressive (SP) or Primary Progressive (PP) MS.

Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology

MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index

ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses

Copyright 1997 - 2010:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.